-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎The content team editor of WuXi AppTec On July 14, Eli Lilly and Company announced the acquisition of Protomer Technologies ("Protomer").
With the realization of future development and commercial milestones, the potential value of the transaction could exceed 10 Billion dollars
.
Protomer is committed to using its proprietary peptide and protein engineering platform to develop a new generation of protein therapies that can sense glucose or other protein activity regulators
.
The company's main product under development is an insulin that can sense glucose, which can be automatically activated according to the blood sugar level of diabetic patients, helping patients to control their blood sugar levels more effectively and safely
.
Protomer founded in 2015, the company based on chemical biological sensor molecule protein engineering (MEPS) using the internet to develop small molecule control, with an adjustable active therapeutic polypeptides and proteins
.
This means that the new generation of therapies generated by this technology can still be rapidly activated by small molecules or inhibit their activity after being injected into the human body
.
It may provide stronger specificity for therapies.
For example, potential therapies can only be activated by small molecules expressed in target tissues, thereby reducing the off-target effects of drugs
.
Protomer has used this method to develop a series of drug candidates under development, including glucose-responsive insulin that can sense glucose levels in the blood and automatically activate as needed throughout the day
.
Image source: Protomer's official website "Lilly has been working hard for a long time to make the lives of diabetic patients better
.
Glucose-sensing insulin is the next frontier.
By improving the efficacy and safety of insulin therapy, it has the potential to transform the treatment and quality of life of diabetic patients
.
"Dr.
Ruth Gimeno, Vice President of Diabetes Research and Clinical Development, Eli Lilly, said, "Protomer's glucose-sensing insulin project based on its proprietary MEPS platform is showing great prospects.
Eli Lilly is pleased to be able to use the company's innovative technology to enhance our Diabetes pipeline
.
"Reference: [1] Lilly Announces Acquisition of Protomer Technologies.
Retrieved July 14, 2021, from https://investor.
lilly.
com/news-releases/news-release-details/lilly-announces-acquisition-protomer-technologies [2] Protomer Therapeutics.
Retrieved July 14, 2021, from https:// Note: This article aims to introduce the progress of medical and health research, not a treatment plan recommendation
.
If you need treatment plan guidance, please go to a regular hospital See a doctor
.
With the realization of future development and commercial milestones, the potential value of the transaction could exceed 10 Billion dollars
.
Protomer is committed to using its proprietary peptide and protein engineering platform to develop a new generation of protein therapies that can sense glucose or other protein activity regulators
.
The company's main product under development is an insulin that can sense glucose, which can be automatically activated according to the blood sugar level of diabetic patients, helping patients to control their blood sugar levels more effectively and safely
.
Protomer founded in 2015, the company based on chemical biological sensor molecule protein engineering (MEPS) using the internet to develop small molecule control, with an adjustable active therapeutic polypeptides and proteins
.
This means that the new generation of therapies generated by this technology can still be rapidly activated by small molecules or inhibit their activity after being injected into the human body
.
It may provide stronger specificity for therapies.
For example, potential therapies can only be activated by small molecules expressed in target tissues, thereby reducing the off-target effects of drugs
.
Protomer has used this method to develop a series of drug candidates under development, including glucose-responsive insulin that can sense glucose levels in the blood and automatically activate as needed throughout the day
.
Image source: Protomer's official website "Lilly has been working hard for a long time to make the lives of diabetic patients better
.
Glucose-sensing insulin is the next frontier.
By improving the efficacy and safety of insulin therapy, it has the potential to transform the treatment and quality of life of diabetic patients
.
"Dr.
Ruth Gimeno, Vice President of Diabetes Research and Clinical Development, Eli Lilly, said, "Protomer's glucose-sensing insulin project based on its proprietary MEPS platform is showing great prospects.
Eli Lilly is pleased to be able to use the company's innovative technology to enhance our Diabetes pipeline
.
"Reference: [1] Lilly Announces Acquisition of Protomer Technologies.
Retrieved July 14, 2021, from https://investor.
lilly.
com/news-releases/news-release-details/lilly-announces-acquisition-protomer-technologies [2] Protomer Therapeutics.
Retrieved July 14, 2021, from https:// Note: This article aims to introduce the progress of medical and health research, not a treatment plan recommendation
.
If you need treatment plan guidance, please go to a regular hospital See a doctor
.
